Vaccitech plc (VACC) Bundle
Vaccitech plc stands at the intersection of ambition and measurable progress, with a mission to harness its proprietary technology to deliver transformative, durable vaccines and T cell therapies for infectious diseases and cancer, a vision that has driven strategic alliances-including work with CEPI-and a set of core values centered on Innovation, Integrity, Collaboration, Accountability and Sustainability; these commitments are reflected in concrete results-record revenues of £50 million in fiscal 2023 (a 75% year‑over‑year increase) alongside substantial investment in R&D totaling £45 million in 2023 (up 20% from 2022)-underscoring how patient‑centric development, strategic partnerships with major pharma and research institutions, and focused resource allocation are accelerating Vaccitech's clinical pipeline and global reach while keeping durable, accessible immunotherapies at the forefront of its purpose
Vaccitech plc (VACC) Intro
Overview Vaccitech plc (VACC) is a biotechnology company focused on developing transformative vaccines and T cell therapies for infectious diseases and cancer. Established to advance innovative immunotherapies, Vaccitech leverages proprietary vaccine platforms and T cell technologies to address global health needs and accelerate translational research into the clinic. Strategic partnerships with major pharmaceutical companies and research institutions have been pivotal in advancing Vaccitech's clinical pipeline and expanding its market presence. Read more background and context here: Vaccitech plc (VACC): History, Ownership, Mission, How It Works & Makes Money Mission Statement Vaccitech's mission centers on delivering transformative immunotherapies that prevent and treat disease by harnessing the power of the immune system. Core elements include:- Develop safe, effective vaccines and T cell therapies for global infectious diseases and cancer
- Translate cutting-edge immunology into scalable clinical solutions
- Ensure broad patient access through strategic collaborations and licensing
- Leading in next-generation vaccine platforms and cellular immunotherapies
- Creating global impact through equitable distribution and technology transfer
- Becoming a preferred development partner for industry and academia
- Scientific excellence: rigorous, evidence-driven research and development
- Patient-centricity: prioritizing safety, efficacy, and accessibility for diverse populations
- Collaboration: partnering with pharma, academia, and public health bodies to accelerate impact
- Integrity: transparent governance, ethical conduct, and responsible data stewardship
- Innovation: sustained investment in novel platforms and translational science
| Metric | 2022 | 2023 | YoY Change |
|---|---|---|---|
| Revenue (GBP) | £28.6 million | £50.0 million | +75% |
| R&D Expenditure (GBP) | £37.5 million | £45.0 million | +20% |
| Clinical Partnerships (active) | 6 | 8 | +33% |
| Employees (approx.) | 120 | 140 | +16.7% |
- Collaborations with major pharmaceutical companies and research institutions to co-develop candidates and share clinical expertise
- Partnerships enabling expanded manufacturing capacity and global trial enrollment
- Active pipeline programs across infectious disease and oncology leveraging platform versatility
- Designing trials and therapies with diverse patient populations and real-world applicability in mind
- Commitment to affordability and access through licensing strategies and global partnerships
- Focus on measurable clinical benefit and long-term immune protection
Vaccitech plc (VACC) - Overview
Vaccitech plc (VACC) centers its R&D and corporate strategy around a concise mission: to harness proprietary technology to create transformative and durable vaccines and T cell therapies for infectious diseases and cancer. This mission emphasizes long-term clinical benefit, broad disease scope, and differentiation through platform innovation.- Mission statement: Harness proprietary technology to create transformative and durable vaccines and T cell therapies for infectious diseases and cancer.
- Focus areas: Infectious diseases (preventive and therapeutic vaccines) and oncology (T cell-driven therapies).
- Platform emphasis: Proprietary viral-vectored prime-boost and T cell-focused approaches to induce durable cellular immunity.
| Attribute | Value / Note |
|---|---|
| Founded | 2016 |
| Headquarters | Oxford, United Kingdom |
| Public ticker | VACC (London / other listings vary by period) |
| Employees (approx.) | ~120 (R&D and corporate staff) |
| Clinical-stage programs | 3 major programs in clinical development (therapeutic HBV, pan-coronavirus, oncology-targeted T cell therapy) |
| Historical fundraising / financings | Multiple equity and partnership financings since IPO / public listing to fund clinical programs and platform expansion |
- Durability of response - develop prime-boost regimens and T cell-oriented constructs to elicit long-lived cellular immunity.
- Platform leverage - apply proprietary vectors and antigen-design know-how across infectious and oncologic indications to achieve economies of scale in R&D.
- Translational rigor - advance candidates through phased clinical trials with immunologic and clinical endpoints to demonstrate sustained benefit.
- Collaborations & partnerships - selectively partner with larger biopharma and academic centers to accelerate late‑stage development and commercialization.
| Program | Indication | Clinical status (as of mid‑2024) |
|---|---|---|
| VTP series (T cell vaccine platform) | Therapeutic HBV | Clinical-stage trials with immunologic and virologic endpoints |
| Pan‑coronavirus program | Broad coronavirus vaccine | Early‑to‑mid clinical development / exploratory trials |
| Oncology T cell therapy candidates | Selected solid tumors | Early clinical / translational studies |
- Science-led innovation - prioritizing platform science and translational evidence to inform program advancement.
- Durability & patient impact - measuring success by long-term clinical benefit, not only short-term response.
- Collaboration & openness - working with academic and industry partners to scale development and access.
- Ethical development - commitment to rigorous safety evaluation and regulatory compliance in clinical programs.
| Metric | Purpose / Target |
|---|---|
| Durable responders (%) | Proportion of vaccinated/treated subjects maintaining response at pre‑specified long‑term timepoints (e.g., 6-12 months) |
| Number of clinical trials | Expansion of clinical evidence base across indications (growth target year‑over‑year) |
| Preclinical-to-clinic transition time (months) | Speed of advancing candidates from lead selection to first‑in‑human studies |
| Strategic partnerships formed | Number & quality of collaborations to enable late‑stage development and commercialization |
- Clinical readouts and durability data drive valuation inflection points and partner interest.
- Successful platform demonstrations enable broader indication expansion and licensing opportunities.
- Operational cash runway and R&D spend profile determine the pace at which programs can be advanced to value‑generating milestones.
Vaccitech plc (VACC) - Mission Statement
Vaccitech plc (VACC) positions its mission around developing next-generation vaccines and immunotherapies to prevent and treat serious infectious diseases and cancers. The company emphasizes translational science, robust clinical development, and strategic collaborations to move promising candidates from discovery to global deployment.- Mission focus: deliver durable, T-cell-driven immunity using viral vector and protein platforms.
- Priority areas: chronic hepatitis B (HBV), oncology therapeutic vaccines, and pandemic preparedness.
- Operational pillars: translational research, clinical development, and partner-led manufacturing and distribution.
- Global health orientation: prioritize programs with high unmet need and epidemic/pandemic relevance.
- Partnership model: co-development and funding collaborations to accelerate timelines and share risk.
- Scientific differentiation: focus on inducing robust cellular immunity alongside humoral responses.
| Metric | Value / Status |
|---|---|
| Founded | 2016 |
| Public listing | NASDAQ (ticker: VACC), 2021 |
| Clinical-stage candidates | 4 (therapeutic and prophylactic indications across HBV, oncology, and epidemic pathogens) |
| Strategic partnerships | CEPI (pandemic preparedness), academic collaborators including Oxford; multiple CMO and biotech partnerships |
| Employees (approx.) | ~100 |
| Most recent reported cash / liquidity (public filings) | Company-disclosed runway and cash position vary by quarterly filing-investors should consult the latest 10-Q / 20-F |
- Platform versatility: heterologous prime-boost regimens and viral vector backbones aimed at strong T-cell responses.
- Translation-to-clinic capability: internal and partnered GMP manufacturing pathways to support trials.
- Focus on measurable clinical endpoints: viral load reduction for HBV, immunologic markers in oncology, and rapid response for epidemic pathogens.
| Investor context | Notes |
|---|---|
| Capital raises / IPO | Completed IPO on NASDAQ in 2021 to fund pipeline advancement and partnerships |
| Revenue profile | Primarily collaboration and grant funding; product revenues dependent on successful approvals/licensing |
| Typical financial profile | R&D‑heavy biotech: recurring net losses while advancing clinical pipeline; cash runway and burn rates disclosed in quarterly filings |
Vaccitech plc (VACC) - Vision Statement
Vaccitech plc (VACC) envisions becoming a leading global developer of T-cell‑focused immunotherapies and vaccines that transform prevention and treatment across infectious disease and oncology. The vision emphasizes durable immune protection, scalable manufacturing, and partnerships that accelerate translation from bench to bedside.- Deliver first-in-class and best-in-class immunotherapies driven by T-cell biology.
- Scale access globally via strategic collaborations and licensing models.
- Demonstrate clear clinical and commercial value through rigorous evidence and cost-effective manufacturing.
Core Values
- Innovation - At the heart of Vaccitech's operations, innovation drives discovery of novel vaccine platforms and T‑cell therapeutics. The company invests heavily in R&D to advance candidates from discovery into clinical trials.
- Integrity - High ethical standards guide interactions with patients, regulators, investors, and partners, underpinning clinical trial conduct, reporting, and corporate governance.
- Collaboration - Strategic alliances with academic institutions, biopharma partners, and public‑health organizations amplify scientific capabilities and accelerate development timelines.
- Accountability - Clear ownership of milestones, transparent reporting, and performance metrics ensure teams are responsible for advancing programs and stewarding resources.
- Sustainability - Operational decisions consider environmental impact and long‑term resource stewardship, from lab operations to supply chain choices.
How These Values Guide Strategy and Operations
- R&D prioritization aligned to T‑cell platform strengths and unmet medical needs, balancing infectious disease and oncology pipelines.
- Partnership-led commercialization strategy to leverage external capabilities and share development risk.
- Financial discipline to extend runway while progressing select clinical programs and enabling peak value inflection points.
| Metric | Value (most recent available) |
|---|---|
| Headquarters | Oxford, United Kingdom |
| Primary focus | T‑cell immunotherapies and vaccines (infectious disease & oncology) |
| NASDAQ ticker | VACC |
| Employees (approx.) | ~60-120 (R&D and corporate personnel) |
| Reported cash & equivalents (most recent fiscal) | ~$40-80 million (cash position varies by quarter) |
| R&D expenditure (latest annual) | ~$20-60 million |
| Clinical programs | Multiple programs across prophylactic vaccines and oncology T‑cell candidates |
Examples of Value in Action
- Innovation: Progression of platform-derived candidates into clinical trials demonstrating T‑cell responses in humans.
- Integrity: Regulatory-compliant trial conduct with data transparency in disclosures and filings.
- Collaboration: Strategic partnerships and licensing arrangements that supplement internal capabilities and expand development reach.
- Accountability: Program milestone tracking tied to budgetary controls to preserve runway for priority assets.
- Sustainability: Operational initiatives to reduce waste and optimize resource use in laboratory and manufacturing activities.
For an investor-focused breakdown of financials and performance context, see: Breaking Down Vaccitech plc (VACC) Financial Health: Key Insights for Investors
0 0 0
Vaccitech plc (VACC) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.